Rapamycin Holdings Plans Tests of Old Immune Drug in Prostate Cancer

Executives at Rapamycin Holdings believe a decades-old drug used to prevent organ transplant rejection could find a new use as a treatment for prostate cancer, and hope to  begin a clinical trial as soon as this summer.